Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4165
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohnson, D.en
dc.contributor.authorCostello, S. P.en
dc.contributor.authorGhaly, S.en
dc.contributor.authorConnor, S. J.en
dc.contributor.authorBegun, J.en
dc.contributor.authorChristensen, B.en
dc.contributor.authorLewindon, P.en
dc.contributor.authorWard, M. G.en
dc.contributor.authorAysha, A. A.en
dc.contributor.authorRentsch, C.en
dc.contributor.authorPrentice, R.en
dc.contributor.authorBryant, R. V.en
dc.date.accessioned2022-11-07T23:50:00Z-
dc.date.available2022-11-07T23:50:00Z-
dc.date.issued2020en
dc.identifier.citation50, (7), 2020, p. 798-804en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/4165-
dc.description.abstractThe COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.L20055440662020-07-20 <br />2020-07-22 <br />en
dc.language.isoenen
dc.relation.ispartofInternal Medicine Journalen
dc.titlePractical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease facultyen
dc.typeArticleen
dc.identifier.doi10.1111/imj.14889en
dc.subject.keywordspublic healthen
dc.subject.keywordsrisk factoren
dc.subject.keywordssmoking cessationen
dc.subject.keywordsulcerative colitisen
dc.subject.keywordsvaccinationen
dc.subject.keywordsvirus transmissionen
dc.subject.keywordsrisk assessmenten
dc.subject.keywordsadalimumabazathioprineen
dc.subject.keywordsbudesonideen
dc.subject.keywordscorticosteroiden
dc.subject.keywordsgolimumaben
dc.subject.keywordsimmunomodulating agenten
dc.subject.keywordsinfliximaben
dc.subject.keywordsJanus kinase inhibitoren
dc.subject.keywordsmercaptopurineen
dc.subject.keywordsmesalazineen
dc.subject.keywordsmethotrexateen
dc.subject.keywordstofacitiniben
dc.subject.keywordsustekinumaben
dc.subject.keywordsvedolizumaben
dc.subject.keywordsarticleen
dc.subject.keywordscoronavirus disease 2019en
dc.subject.keywordsCrohn diseaseen
dc.subject.keywordsdiet therapyen
dc.subject.keywordshealth care qualityen
dc.subject.keywordshumanen
dc.subject.keywordsimmunosuppressive treatmenten
dc.subject.keywordsinflammatory bowel diseaseen
dc.subject.keywordspandemicen
dc.subject.keywordspatient careen
dc.subject.keywordspriority journalen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2005544066&from=exporthttp://dx.doi.org/10.1111/imj.14889 |en
dc.identifier.risid2627en
dc.description.pages798-804en
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeArticle-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

104
checked on Feb 14, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.